ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,995,129 | -48.6% | 989,410 | 0.0% | 0.88% | -49.6% |
Q1 2024 | $13,604,388 | +49.5% | 989,410 | 0.0% | 1.74% | +70.3% |
Q4 2023 | $9,102,572 | -24.0% | 989,410 | -50.0% | 1.02% | -21.6% |
Q3 2023 | $11,971,862 | +106.4% | 1,978,820 | +164.7% | 1.31% | -12.4% |
Q2 2023 | $5,800,988 | +36.1% | 747,550 | 0.0% | 1.49% | -60.1% |
Q1 2023 | $4,261,035 | -3.2% | 747,550 | 0.0% | 3.74% | -9.2% |
Q4 2022 | $4,403,070 | +84.1% | 747,550 | 0.0% | 4.12% | +85.5% |
Q3 2022 | $2,392,000 | -28.6% | 747,550 | 0.0% | 2.22% | -22.0% |
Q2 2022 | $3,349,000 | -16.1% | 747,550 | 0.0% | 2.85% | +22.8% |
Q1 2022 | $3,992,000 | -63.7% | 747,550 | 0.0% | 2.32% | -62.9% |
Q4 2021 | $10,989,000 | -32.4% | 747,550 | -3.8% | 6.25% | -20.9% |
Q3 2021 | $16,251,000 | -7.8% | 777,193 | -22.0% | 7.90% | +38.0% |
Q2 2021 | $17,632,000 | -27.8% | 996,734 | 0.0% | 5.72% | -30.0% |
Q1 2021 | $24,420,000 | -48.5% | 996,734 | -28.8% | 8.17% | -18.6% |
Q4 2020 | $47,405,000 | – | 1,400,435 | – | 10.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 496,893 | $16,760,000 | 14.90% |
Svennilson Peter | 4,768,181 | $160,831,000 | 13.45% |
Invus Financial Advisors, LLC | 1,007,576 | $33,986,000 | 12.28% |
EcoR1 Capital, LLC | 2,642,218 | $89,122,000 | 6.58% |
Foresite Capital Management IV, LLC | 125,000 | $4,216,000 | 2.05% |
Orbimed Advisors | 2,921,967 | $98,558,000 | 1.39% |
Casdin Capital, LLC | 251,515 | $8,484,000 | 0.50% |
MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 191,568 | $6,462,000 | 0.50% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 300,000 | $10,119,000 | 0.30% |
EMERALD ADVISERS, LLC | 186,140 | $6,279,000 | 0.27% |